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A B S T R A C T
The purpose of this study was to develop different injectable nanosized drug delivery systems (NDDSs)
i.e. liposome, lipid nanocapsule (LNC) and polymeric nanocapsule (PNC) encapsulating apigenin (AG) and
compare their characteristics to identify the nanovector(s) that can deliver the largest quantity of AG
while being biocompatible. Two liposomes with different surface characteristics (cationic and anionic), a
LNC and a PNC were prepared. A novel tocopherol modiﬁed poly(ethylene glycol)-b-polyphosphate
block-copolymer was used for the ﬁrst time for the PNC preparation. The NDDSs were compared by their
physicochemical characteristics, AG release, storage stability, stability in serum, complement
consumption and toxicity against a human macrovascular endothelial cell line (EAhy926). The diameter
and surface charge of the NDDSs were comparable with previously reported injectable nanocarriers. The
NDDSs showed good encapsulation efﬁciency and drug loading. Moreover, the NDDSs were stable during
storage and in fetal bovine serum for extended periods, showed low complement consumption and were
non-toxic to EAhy926 cells up to high concentrations. Therefore, they can be considered as potential
injectable nanocarriers of AG. Due to less pronounced burst effect and extended release characteristics,
the nanocapsules could be favorable approaches for achieving prolonged pharmacological activity of AG
using injectable NDDS.
© 2017 Elsevier B.V. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Pharmaceutics
journal homepage: www.elsev ier .com/locate / i jpharm1. Introduction
Apigenin (AG) is a natural plant ﬂavonoid (40, 5, 7,-trihydroxy-
ﬂavone), widely found in many common fruits and vegetables e.g.
oranges, grapefruit, chamomile, tea, parsley, onions and wheatAbbreviations: AG, apigenin; AL-AG, apigenin loaded anionic liposome; AL-blank
cholesterol; CL-AG, apigenin loaded cationic liposome; CL-blank, empty cationic 
dimethylaminoethane)-carbamoyl]cholesterol hydrochloride; DLS, dynamic light scatter
phosphoethanolamine; DPPC,1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DSPE-mPEG
glycol)-2000] ammonium salt; EE, entrapment efﬁciency; FBS, fetal bovine serum; HEP
liquid chromatography; Kolliphor1HS15, macrogol 15 hydroxystearate; Labrafac Lipophi
hydrogenated phosphatidylcholine from soybean; LNC, lipid nanocapsule; LNC-AG, 
mononuclear phagocytic system; MWCO, molecular weight cut-off; NaCl, sodium chl
nanoparticle tracking analysis; PDI, polydispersity index; PEG, poly(ethylene glycol); PN
blank, empty polymeric nanocapsule; PS80, polysorbate 80; TEM, transmission electro
* Corresponding author at: INSERM U1066, MIcro et Nanomédecines Translationnell
E-mail addresses: reatul.karim@ulg.ac.be, reatulkarim@gmail.com (R. Karim).
http://dx.doi.org/10.1016/j.ijpharm.2017.04.064
0378-5173/© 2017 Elsevier B.V. All rights reserved.sprouts (Patel et al., 2007; Zheng et al., 2005). It showed a number
of signiﬁcant beneﬁcial bioactivities i.e. anti-oxidant (Romanova
et al., 2001), anti-inﬂammatory (Lee et al., 2007) and anti-cancer
properties (Shukla and Gupta, 2010). Despite the numerous
positive effects, AG is characterized by very low aqueous solubility, empty anionic liposome; BCS, Biopharmaceutical Classiﬁcation System; Chol,
liposome; DC-, dimethylaminoethane-carbamoyl chain; DC-Chol, 3ß-[N-(N',N'-
ing; DMEM, Dulbecco’s modiﬁed Eagle’s medium; DOPE, 1,2-dioleoyl-sn-glycero-3-
2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene
ES, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; HPLC, high-performance
le WL1349, caprylic/capric triglycerides; LDH, lactate dehydrogenase; Lipoid S PC-3,
apigenin loaded lipid nanocapsule; LNC-blank, empty lipid nanocapsule; MPS,
oride; NDDS, nanosized drug delivery system; NHS, normal human serum; NTA,
C, polymeric nanocapsule; PNC-AG, apigenin loaded polymeric nanocapsule; PNC-
n microscopy; UPW, ultra-pure water.
es, IBS-CHU ANGERS, 4 rue Larrey, 49933 Angers Cedex 9, France.
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1997) and it is then a Biopharmaceutical Classiﬁcation System
(BCS) II molecule (Zhang et al., 2012). Taking these into account,
the development of its injectable formulations, useful to overcome
the constraint of low oral bioavailability, is challenging as AG is
insoluble in most biocompatible solvents (Zhao et al., 2013).
Therefore, use of AG for in vivo studies is limited.
One of the most interesting strategies to overcome this issue is
to encapsulate the AG in nanosized drug delivery systems (NDDSs).
NDDSs, also known as nanocarriers, are promising and versatile
approach for delivery of hydrophobic drugs (Karim et al., 2017;
Lainé et al., 2014) with several advantageous properties i.e.
adaptable characteristics with easily modiﬁable surface, capacity
to entrap large quantities of hydrophobic drug and protect it from
degradation, improve bioavailability, release drug in a controlled
manner over extended period, prolong plasma circulation half-life
and increase pharmacological effects (Peer et al., 2007; Zhang et al.,
2008). Moreover, they can be modiﬁed for site-speciﬁc drug
delivery which reduce side-effects and improve the therapeutic
window (Karim et al., 2016). Among various nanocarriers,
liposome (Eavarone et al., 2000; Felgner and Ringold, 1989), lipid
nanocapsule (LNC) (Allard et al., 2008; Lamprecht et al., 2002) and
polymer-based nanocapsule (PNC) (De Melo et al., 2012; Mora-
Huertas et al., 2010) have been widely studied. Although these
nanocarriers can be generally considered as vesicular systems,
their composition and morphology are signiﬁcantly different from
each other. Liposomes have structural similarities with cellular
organelles and are made of phospholipid bilayer(s) surrounding an
aqueous core. Due to their particular structure, liposomes are
capable to encapsulate both lipophilic drugs (in the lipidic-bilayer
(s)) and hydrophilic drugs (in the core). In comparison, PNCs have a
solid polymer-shell surrounding an oily core, where lipophilic
drugs are encapsulated. Structure of LNCs is a hybrid among PNCs
and liposomes; characterized by an oily-liquid core surrounded by
a solid lipid shell. All three NDDSs, i.e. liposome (Sharma et al.,
1996), LNC (Zanotto-Filho et al., 2013) and PNC (Mora-Huertas
et al., 2012) have been widely studied to improve the delivery of
poorly water soluble drugs. Additionally, these nanocarriers can be
designed for parenteral administration, in order to bypass
absorption process and maximize the drug bioavailability. AG-
loaded injectable NDDSs can be particularly beneﬁcial for
treatment of numerous types of cancers (e.g. colon cancer, brain
cancer, breast cancer, liver cancer, prostate cancer, cervical cancer,
thyroid cancer, skin cancer, gastric cancer etc.) due to the
promising activity of AG [reviewed in detail by Patel et al., Shukla
and Gupta] (Patel et al., 2007; Shukla and Gupta, 2010) and the
capability of NDDSs to extravasate and preferentially accumulate
in tumors by enhanced permeability and retention effect (Fu et al.,
2009; Iyer et al., 2006). However, after administration into blood
circulation, the NDDSs can be destabilized by plasma proteins
leading to premature drug release. Moreover, they can form
aggregates or adsorb a signiﬁcant amount of plasma proteins and
form a “protein-corona” (Palchetti et al., 2016). If opsonins are
adsorbed on the surface, the NDDSs are subsequently captured and
rapidly eliminated from the systemic circulation by mononuclear
phagocytic system (MPS) (a part of the immune system) which
restricts their blood circulation time. Formation of aggregates can
also result rapid NDDS uptake by MPS (He et al., 2010). Therefore,
stability of NDDSs in serum and low complement protein
consumption are necessary for developing of safe and long-
circulating nano-therapeutics for future clinical use (Li et al., 2015;
Moore et al., 2015).
Different NDDSs are prepared from diverse ingredients and
have variations in morphology, surface characteristics, drug
loading capacity, drug release rates, toxicity etc. The purpose of
this study was to develop and compare the characteristics ofdifferent injectable AG-NDDSs in order to identify the nanocarrier
(s) that can deliver the largest quantity of AG while being
biocompatible. Two liposomes with different surface character-
istics (anionic and cationic), a LNC and a PNC were prepared. A
novel block-copolymer i.e. tocopherol modiﬁed poly(ethylene
glycol) (PEG)-b-polyphosphate (Fig. S1 in Supplementary material)
(Vanslambrouck, 2015) was used for the ﬁrst time for PNC
preparation. Different techniques were used for preparation of the
nanocarriers, and the so-obtained NDDSs were physicochemically
characterized. Moreover, stability of the NDDSs in fetal bovine
serum (FBS) and their complement protein consumption in normal
human serum (NHS) were evaluated. Toxicity of the nanocarriers
was assessed against a human macrovascular endothelial cell line
to evaluate their biocompatibility.
2. Materials and methods
2.1. Materials
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dio-
leoyl-sn-glycero-3-phosphoethanolamine (DOPE), 3ß-[N-(N',N'-
dimethylaminoethane)-carbamoyl]cholesterol hydrochloride
(DC-Chol) and 1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-[methoxy(polyethylene glycol)-2000] ammonium salt
(DSPE-mPEG2000) were purchased from Avanti Polar Lipids, Inc.
(USA). Cholesterol (Chol), 4-(2-hydroxyethyl)piperazine-1-etha-
nesulfonic acid (HEPES), sodium chloride (NaCl) and macrogol 15
hydroxystearate (Kolliphor1 HS15) were purchased from Sigma-
Aldrich (Germany). Hydrogenated phosphatidylcholine from
soybean (Lipoid S PC-3) was provided from Lipoid GmbH
(Germany), caprylic/capric triglycerides (Labrafac Lipophile
WL1349) was supplied by Gattefosse (France). Polysorbate 80
(PS80) was purchased from Merck (Germany). AG was purchased
from Indis NV (Belgium). The tocopherol modiﬁed PEG-b-poly-
phosphate copolymer (PEG120-b-(PBP-co-Ptoco)9) was synthesized
by organocatalyzed ring-opening polymerization (Clement et al.,
2012) of a butenylphosphate ring from a monomethoxy(polyeth-
ylene glycol) macroinitiator (MeO-PEG-OH, MW 5000 g/mol,
Aldrich) (Yilmaz et al., 2016) followed by the grafting of a
tocopherol derivative on the polyphosphate backbone by thiol-ene
reaction (Baeten et al., 2016) (Fig. S1 in Supplementary material).
Ultra-pure water (UPW) was obtained from a Millipore ﬁltration
system. All the other reagents and chemicals were of analytical
grade. Normal human serum (NHS) was provided by the
“Etablissement Français du Sang” (Angers, France). Sheep eryth-
rocytes and hemolysin were purchased from Eurobio (France).
EAhy926 cells (human umbilical endothelial cell line), Penicillin-
Streptomycin, and Dulbecco’s modiﬁed Eagle’s medium (DMEM)
were provided by Lonza (Belgium). Fetal bovine serum (FBS) was
provided by Biologicals Industries (USA).
2.2. Preparation of NDDSs
2.2.1. Preparation of cationic liposomes and anionic liposomes
The cationic and anionic liposome formulations (CL-AG and AL-
AG respectively, composition shown in Table 1, CL composition is
modiﬁed from (Bellavance et al., 2010)) were prepared by thin
lipid-ﬁlm hydration, extrusion (Wei et al., 2015) and PEG post-
insertion method. Brieﬂy, AG and the excipients were dissolved in
absolute ethanol and then dried in a rotary evaporator at 30 C for
1 h to form a dry lipid ﬁlm. Subsequently, the dried ﬁlm was
hydrated with HEPES buffer (pH 7.4) and hardly agitated for 15 min.
Afterwards, the lipid dispersion was extruded consecutively
through 0.4 mm (3), 0.2 mm (3) and 0.1 mm (3) polycarbonate
membranes (Nucleopore1, Whatman) at 50 C (above phase
transition temperature of DPPC) to obtain primary liposomes.
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primary liposomes by post-insertion technique, by incubation at
50 C for 30 min. The liposome formulations were then puriﬁed by
dialysis (MWCO 20 kD, Spectra/Por1 biotech grade cellulose ester
membrane, SpectrumLabs, Netherlands) against HEPES buffer (pH
7.4) at 4 C for 2  1 h cycles.
Blank liposomes (CL-blank and AL-blank) were prepared
following the same procedure but without the addition of AG.
2.2.2. Preparation of lipid nanocapsules
The apigenin-loaded LNCs (LNC-AG) were prepared using phase
inversion temperature technique (Laine et al., 2014). In brief, AG
(0.2% w/w), Kolliphor1 HS15 (16.5% w/w), Lipoid1 S PC-3 (1.5% w/
w), Labrafac Lipophile WL1349 (20.1% w/w), DSPE-mPEG2000 (1.9%
w/w), NaCl (1.7% w/w) and UPW (58% w/w) were mixed under
magnetic stirring at 60 C. Three heating-cooling cycles were
performed between 90 C and 60 C. During the last cooling step,
when the temperature was in the phase inversion zone (78–83 C),
ice-cold UPW was added (ﬁnal concentration 69.8% w/w) to induce
irreversible shock and form the LNC-AG. The nanocapsules were
then diluted with HEPES buffer and passed through 0.2 mm
cellulose acetate ﬁlter to remove any aggregates. Puriﬁcation was
done by dialysis method as described in 2.2.1.
Blank LNCs (LNC-blank) were prepared by the same procedure
as LNC-AG, but without the addition of AG.
2.2.3. Preparation of polymer-based nanocapsules
The apigenin-loaded PNCs (PNC-AG) were prepared using
nanoprecipitation technique followed by solvent evaporation
under vacuum (Mora-Huertas et al., 2012). In short, AG (1.2% w/
w), PEG120-b-(PBP-co-Ptoco)9 (20.1% w/w), Lipoid1 S PC-3 (10.8%
w/w), Labrafac Lipophile WL1349 (67.9% w/w) were dissolved in
ethanol:acetone (1:3 v/v). Subsequently, the solution was slowly
injected (0.8 mm needle) into an aqueous solution of PS80 (0.25%
w/v) under magnetic stirring at 400 rpm. After 10 min stirring, the
organic solvent was completely removed by evaporation under
reduced pressure at 40 C. The PNC-AG was puriﬁed by dialysis
method as described in 2.2.1.
Blank PNCs (PNC-blank) were prepared in the same procedure
as PNC-AG, but without the addition of AG.
2.3. Size distribution, zeta-potential and morphology
The mean diameter and polydispersity index (PDI) of the NDDSs
were determined by dynamic light scattering (DLS) technique using
Zetasizer Nano ZS (Malvern Instruments Ltd, UK). NDDSs were
diluted 100-folds in UPW before the analysis. The measurements
were performed at backscatter angle of 173. The measured average
values were calculated from 3 runs, with 10 measurements within
each run.
Additionally, the size distribution of the NDDSs was determined
using nanoparticle tracking analysis (NTA), which complementsTable 1
Molar ratio of ingredients of CL-AG and AL-AG.
Ingredient Molar ratio
CL-AG AL-AG
DPPC 1 1
DC-Chol 0.77 –
Chol – 0.77
DOPE 0.77 0.77
DSPE-mPEG2000 (during dry lipid ﬁlm formation) 0.01 0.01
DSPE-mPEG2000 (post insertion) 0.04 0.04
AG 0.13 0.13the DLS measurements. The NTA was carried out using the
NanoSight NS300 (Malvern Instruments Ltd, UK). Brieﬂy, the NDDS
samples were diluted to optimum concentrations with UPW and
were infused in the sample chamber using a syringe pump at
30 mL/min rate. A 405 nm laser was used to illuminate the
particles, and their Brownian motion was recorded into three
60 s videos (25 fps) using the sCMOS type camera of the
instrument. Subsequently, the NTA software (NTA 3.2 Dev Build
3.2.16) analyzed the recordings, tracked the motion of the particles
and calculated the diameter of the particles. The experiment was
performed in triplicate.
Zeta potential of the nanocarriers was measured using laser
Doppler micro-electrophoresis technique using Zetasizer Nano ZS
(Malvern Instruments Ltd, UK).
Morphology and size of the NDDSs were visualized by
transmission electron microscopy (TEM) using negative staining
technique. Brieﬂy, a drop of the NDDS dispersion was placed for
30 s on a TEM copper grid (300 mesh) with a carbon support ﬁlm.
The excess dispersion was removed with a ﬁlter paper. Subse-
quently, staining was done by adding a drop of 1% (w/v) aqueous
solution of uranyl acetate on the grid for 1.5 min, followed by
removal of excess solution. The TEM observations were carried out
with a JEOL JEM-1400 transmission electron microscope equipped
with a Morada camera at 100 kV.
2.4. Apigenin dosage via HPLC method
To quantify total (encapsulated and unencapsulated) AG concen-
tration, CL-AG, AL-AG, and LNC-AG were broken by mixing
vigorously with an appropriate volume (7-folds dilution for CL-AG
and AL-AG, 40-folds dilution for LNC-AG) for of ethanol to keep
dissolved AG concentration between 5 and 50 mg/mL. PNC-AG was
processed in the similarway, exceptethanol:acetone (1:3 v/v, 7-folds
dilution) was used as the solvent. To quantify unencapsulated AG
concentration, formulations were placed on centrifugal concentra-
tor devices with polyethersulfone membrane (MWCO 30 kD,
Vivaspin 500, Sartorius AG) and centrifuged at 14500g for 20 min
to separate the free AG from the rest of the formulation. The ﬁltrates
containing unencapsulated AG were collected and ethanol (2-folds)
was added to solubilize any undissolved drug. AG dosage in the
above mentioned samples was performed by a validated method in
a HPLC system (LC Agilent 1100 series, Agilent Technologies,
Belgium). An AlltimaTM HP C18 analytical column (250  4.6 mm,
5 mm, Grace Divison Discovery Sciences, Belgium) was used at 30 C.
UPW and acetonitrile (55:45, v/v) was used as mobile phase. Flow
rate was 1 mL/min, injection volume was 10 mL and AG was
quantiﬁed byan UV detector at l of 340 nm. Analysis of the data was
performed by Open Lab HPLC Agilent software. Retention time for
AG was 4.9 min.
2.5. Entrapment efﬁciency (EE)
EE %ð Þ ¼ Total AG conc: in NDDS  unencapsulated AG conc: in NDDSð Þ  100
Theoritical AG conc: in NDDS
*Determined by HPLC (2.4)
2.6. Mass yield and drug loading capacity
Mass yield of NDDSs was calculated by gravimetric analysis of
the dried NDDSs dispersions. Brieﬂy, 200 mL of NDDSs were freeze-
dried (Drywinner 8, Heto-Holten A/S, Denmark) over a 24 h cycle.
Weight of the dried nanocarriers were measured (weights of
HEPES buffer and NaCl were taken into account) and mass yield (%)
760 R. Karim et al. / International Journal of Pharmaceutics 532 (2017) 757–768was calculated using the following equation:
Mass yield %ð Þ ¼ Weight of200 mL NDDS  100
Theoretical weight of200 mL NDDS
Drug loading capacity was calculated using the following
equation:
Drug loading capacity
mg AG
mg NDDS
 
¼ Amount of AG in200 mL NDDS  ðmgÞ
Weight of200 mL NDDS mgð Þ
*Determined by HPLC (2.4)
2.7. In vitro drug release proﬁle of the NDDSs
In vitro drug release proﬁles of the nanocarriers were studied
with the dialysis method. In brief, 1 mL of AG loaded NDDSs were
taken in a dialysis bag (MWCO 20 kD, Spectra/Por1 biotech grade
cellulose ester membrane, SpectrumLabs, Netherlands) and
dialyzed against HEPES buffer (pH 7.4) (200/1 acceptor/donator
volume ratio to obtain sink condition) at 37 C, stirred at 75 rpm
(SW22, Julabo GmbH, Germany). The concentration of AG was
determined by HPLC method described in 2.4.
2.8. Storage stability
The NDDSs were kept at 4 C and samples were withdrawn at
day 0, 1, 3, 7 and 14. Stability during storage was evaluated by size,
PDI (using method described in 2.3), AG content (using HPLC
method described in 2.4) and AG leakage. The leakage of AG from
NDDSs was assessed using the method to quantify unencapsulated
AG mentioned in Section 2.4.
2.9. Stability of the NDDSs in serum
Stability of the NDDSs in FBS was evaluated by following their
size distribution against time (Li et al., 2015; Palchetti et al., 2016).
The nanocarrier formulations were diluted using HEPES buffer (pH
7.4) to optimum concentrations (200 mg lipid/mL for CL-AG, AL-AG
and PNC-AG; 500 mg lipid/mL for LNC-AG) and mixed with FBS at
1:1 ratio (v/v) at 37 C. The mixture, along with nanocarrier
dispersion and FBS (controls), were incubated at 37 C at 75 rpm in
a shaking water bath (SW22, Julabo GmbH, Germany). At
predetermined time intervals (1 min, 30 min, 1 h, 2 h, 4 h, 6 h
and 24 h), 20 mL of samples were withdrawn, diluted 50-folds with
UPW and size distribution was measured via DLS method
described in 2.3.
2.10. Complement consumption by the NDDSs
Complement activation was evaluated by measuring the
residual hemolytic capacity of NHS towards antibody-sensitized
sheep erythrocytes after exposure to the different NDDSs (CH50
assay) (Cajot et al., 2011). In brief, aliquots of NHS were incubated
with increasing concentrations of the NDDSs at 37 C for 1 h.
Subsequently, the different volumes of the NHS were incubatedTable 2
Physicochemical characteristics of the NDDSs.
Characteristics CL-AG 
Mean diameter (nm)a 144  1 
PDI 0.04  0.01 
Zeta potential (mV) 43.2  1.2 
EE (%) 71  2 
Mass yield (%) 80  3 
Drug loading capacity (mgAG/mgNDDS) 16.5  0.2 
a Measured by DLS.with a ﬁxed volume of hemolysin-sensitized sheep erythrocytes at
37 C for 45 min. The volume of serum that can lyse 50% of the
erythrocytes was calculated (“CH50 units”) for each sample and
percentage of CH50 unit consumption relative to negative control
was determined as described previously (Vonarbourg et al., 2006).
Particle number in the NDDS dispersions was determined by NTA
described in Section 2.3 and particle concentration per mL of NHS
was calculated according to following equation-
Particle number per mL of NHS
¼ Particle conc: in NDDS dispersion  vol: of NDDS addedvol: of NHS
Subsequently, surface area of the NDDSs per mL of NHS was
calculated according to the following equation-
Surface area ¼ Particle number per mL of NHS  p
 ðaverage particle diameterÞ2
The CH50 unit consumption by the different NDDSs were
compared by plotting the percentage of CH50 unit consumption as
a function of their surface area.
2.11. In vitro cytotoxicity of NDDSs on endothelial cell line
The endothelial cells (EAhy926) were seeded in a 96-well plate
at a density of 12.5 103 cells/well and incubated for 24 h. AG
solution (in DMSO) and NDDSs, at a concentration of 0.6 mM to
40 mM, were added to the cells in 200 mL of cell media and
incubated for 24 h. Cytotoxicity of formulations was determined by
evaluating cell viability using methyl tetrazolium (MTS) assay
(CellTiter 961 Aqueous One Solution Cell Proliferation Assay,
Promega, WI, USA) and cell necrosis by lactate dehydrogenase
(LDH) assay (Cytotoxicity Detection KitPLUS, Roche, Basel,
Switzerland), according to manufacturer’s instructions.
2.12. Statistical analysis
Results obtained from the experiments were analyzed statisti-
cally using GraphPad Prism1 software. Mean and standard deviation
(SD) were determined and values are represented as Mean  SD. One
way analysis of variance (ANOVA) was performed in the respective
ﬁelds with Bonferroni post-test to compare among individual
groups,and Dunnett’s post-test to comparewith control.P-value less
than 0.05 (p < 0.05) was considered to be statistically signiﬁcant.
3. Results
3.1. Characteristics of the NDDSs
Particle size and zeta potential of the developed NDDSs
(determined by DLS) are shown in Table 2. The mean hydrodynamic
diameter of the AG loaded liposomes (CL-AG and AL-AG) and the
PNC-AG was comparable (p > 0.5). The sizes of these nanocarriers
were around 143 nm. The mean diameter of the LNC-AG was
signiﬁcantly (p < 0.001) smaller (59 nm) compared to the otherAL-AG LNC-AG PNC-AG
142  6 59  2 145  7
0.12  0.02 0.11  0.03 0.11  0.02
27.4  2.3 24.9  6.0 16.2  4.4
34  1 82  5 84  4
86  5 72  2 81  4
6.5  0.3 6.2  0.5 14.3  0.6
Fig. 2. In vitro drug release from CL-AG (), AL-AG (&), LNC-AG (&) and PNC-AG
(!).
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mean diameter of the CL-AG, AL-AG, LNC-AG and PNC-AG deter-
mined by NTA analysis were 133 nm, 136 nm, 54 nm and 141 nm
respectively. This was in agreement with the results obtained from
DLS. Morphologyof the NDDSswas visualized by TEM images(Fig.1).
The NDDSs were nearly spherical and the liposomes were
unilamellar. Additionally, mean sizes of CL-AG, AL-AG, LNC-AG
and PNC-AG determined by TEM were 111 nm, 214 nm, 55 nm and
87 nm respectively. Mean size (determined by TEM) of CL-AG and
LNC-AG were comparable with the results obtained by DLS and NTA,
whereas average size of AL-AG and PNC-AG were quite dissimilar.
This can possibly occur due to the differences of the physical state of
the samples (dryvs hydratedstate)and sizecalculationtechniques of
TEM compared to DLS (number vs intensity weighted).
The zeta potential of the CL-AG was 43.2 mV and was
signiﬁcantly different (p < 0.001) compared to the other NDDSs,
which were negatively charged. Surface charge of AL-AG, LNC-AG
and PNC-AG were 27.4 mV, 24.9 mV and 16.2 mV respectively.
However, only the zeta potentials of AL-AG and PNC-AG were
signiﬁcantly different (p < 0.05) among these three NDDSs.
EE of the CL-AG was 71% which was signiﬁcantly higher
(p < 0.001) compared to the AL-AG. Moreover, EE of the nano-
capsules were signiﬁcantly higher compared to the CL-AG
(p < 0.05) and AL-AG (p < 0.001) but were comparable (p > 0.05)
with each other (82% for LNC-AG and 84% for PNC-AG).
Mass yields of the NDDSs were between 72 and 85%. The
highest yield mass was observed for AL-AG, followed by LNC-AG,
PNC-AG and CL-AG. No signiﬁcant difference (p > 0.05) was
observed for yield mass of CL-AG and PNC-AG. Drug loading
capacity in CL-AG and PNC-AG were more than 2-fold higher (16.5
and 14.3 mgAG/mgNDDS respectively) compared to AL-AG and
LNC-AG (6.5 and 6.2 mgAG/mgNDDS respectively). Drug loading
capacity of the NDDSs were signiﬁcantly different (p < 0.01) from
each other, except for AL-AG and LNC-AG.
3.2. In vitro drug release proﬁle of the NDDSs
The drug release (%) from the NDDSs was plotted against time to
obtain their drug release proﬁles (Fig. 2). Faster release proﬁlesFig. 1. Representative transmission electron microscopy images were observed for the liposomes in comparison to the nano-
capsules. Although initial release from CL-AGs was slower
compared to the AL-AGs, the liposomes released about 85–91%
drug after 6 h.
In comparison, the nanocapsules showed a biphasic and more
sustained release proﬁle, with a faster release rate up to 8 h,
followed by a much slower rate up to 72 h. Moreover, the release
rates of LNC-AG and PNC-AG were very comparable up to 24 h, with
a release of 54% and 58% drug respectively. However, the drug
release rate of PNC-AG was relatively quicker after 24 h compared
to LNC-AG. After 72 h, the LNC-AG released 63% drug whereas PNC-
AG released 85% drug.
3.3. Storage stability of the NDDSs
Stability of the NDDSs during storage was evaluated using
several parameters i.e. size distribution (mean diameter and PDI),
AG concentration and drug leakage. Mean size and PDI were
determined to evaluate the physical stability of the nanocarriers,
AG concentration will provide information about chemical stability
of the drug within the NDDSs, whereas drug leakage will give
evidence of the robustness of the NDDSs during storage. Size of all
four NDDSs were stable throughout the study period (Fig. 3a).of CL-AG, AL-AG, LNC-AG and PNC-AG (white bar: 200 nm).
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showing that the formulations remained monodispersed.
AG concentrations (% of initial) in the nanocarriers are showed
in Fig. 3b. The AG% in AL-AG, LNC-AG and PNC-AG remained
unaffected, signifying the stability of the drug in these nano-
carriers. However, AG% in CL-AGs gradually reduced to 90% of
initial concentration after 14 days, demonstrating possible drug
degradation in this NDDS. No drug leakage from any of the NDDSs
was observed up to 14 days.
3.4. Stability of the NDDSs in serum
Stability of the NDDSs in serum was evaluated by following
their size distribution in FBS (at 37 C, 75 rpm) against time using
DLS in order to detect any alteration in their diameter and to
determine possible particle destabilization, aggregation or protein
corona formation. Additionally, the NDDS dispersions and FBS
were also incubated under same conditions as controls.
As DLS shows size distribution graphs in relative intensity (%),
the height of an unimodal peak will be higher compared to the
same peak in a mixed multimodal sample. Moreover, focusing a
particular size range (e.g. 0–50 nm or 100–300 nm) and getting
information about a speciﬁc peak from a mixture is not possible in
DLS. Therefore, peak heights of NDDS-FBS mixtures were normal-
ized in the overlaid size graphs (FBS, NDDS, NDDS +FBS) (Fig. 4a)
for easier qualitative comparison with the controls, while position
of the normalized peaks still provided information about possible
corona formation.
Throughout the study period, size distributions of the control
NDDSs were unimodal and their diameter did not change (Fig. 4).
Therefore, no signs of particle aggregation or degradation were
observed. Size distribution of the control FBS remained bimodal
(more frequent, peaks around 10–15 nm and 30–50 nm) or
trimodal (less frequent additional small peak around 200 nm)
up to 6 h of the study. However, larger aggregates were often
observed in control FBS after 24 h with peaks around 300–500 nm.
Up to 6 h, size distributions of the NDDS-FBS mixtures for CL-
AG, AL-AG and PNC-AG were trimodal, showing the peaks of the
free proteins (around 10–15 nm and 30–50 nm) and the NDDSs
(peaks around 120–150 nm). Position of the peaks of NDDS-FBS
mixtures were comparable with the corresponding control peaks.
However, size distribution graph for LNC-AG-FBS mixture was
bimodal as one of the peaks (around 30–50 nm) of FBS overlapped
with the peak of LNC-AG, resulting a wider combined peak instead
of two separate peaks. Moreover, higher concentration of LNC-AG
was necessary, compared to CL-AG, AL-AG and PNC-AG, to observe
its peaks in FBS due to the overlapping peaks. However, the peak of
the NDDS was identiﬁable due to the increased height of theFig. 3. Stability proﬁles of the NDDSs at 4 C up to 14 days: a) Mean diameter of CL-A
concentration (% of day 0) in CL-AG (), AL-AG (&), LNC-AG (&) and PNC-AG (!).second peak in the LNC-AG-FBS mixture. The position of LNC-AG-
FBS peaks were comparable with the controls (LNC-AG and FBS),
like the other NDDSs. Therefore, up to 6 h, none of the NDDSs
showed any signs of particle aggregation or adsorbing large
amount of serum proteins, demonstrating their colloidal stability
in serum.
The respective peaks of CL-AG, AL-AG and LNC-AG in FBS shifted
toward larger diameters after 24 h. However, it is difﬁcult to come
into conclusion that the augmentation of diameter is due to protein
adsorption and corona formation around the NDDS surface, or due
to particle aggregation as the control FBS showed aggregated
particle peaks around 300–500 nm after 24 h. However, in the
experiment with PNC-AG, the NDDS peak in FBS mixture did not
shift toward higher value after 24 h, and the control FBS also did
not show any peaks of large aggregated particles.
3.5. Complement consumption by the NDDSs
The complement consumption by the different NDDSs were
measured by CH50 assay. Their percentage of CH50 unit
consumption was plotted as a function of the particle surface
area per mL of NHS (Fig. 5). As usually observed, the complement
consumption for the four nanocarriers was increasing with the
amount of NDDS added in NHS. The LNC-AG showed the lowest
CH50 consumption and reached only 2.1% at 800 cm2/mL of NHS.
The complement consumption of AL-AG and CL-AG increased
gradually and reached 17.5% at 852 cm2/mL of NHS and 26.8% at
752 cm2/mL of NHS respectively. Although the PNC-AG consumed
higher CH50 units at smaller surface areas than the others, its
consumption increased slowly when more nanoparticles were
added and reached 23.7% at 838 cm2/mL of NHS.
3.6. In vitro cytotoxicity of the NDDSs on endothelial cells
Cytotoxicity of AG solution and the NDDSs on EAhy926, a
human endothelial cell line, was evaluated in vitro by two different
assays i.e. MTS and LDH assay (Fig. 6). The drug solution did not
show any signiﬁcant toxicity in both assays. The CL-AG and CL-
blank showed no signs of toxicity up to 2.5 mM. However,
signiﬁcant reduction of cell viability was revealed at concen-
trations 10 mM, corresponding to 171 mg/mL of CL-AG (Table 3).
Correspondingly, signiﬁcant necrosis was observed in LDH assay at
similar concentrations of CL-blank and PNC-blank. However, the
AL-blank, AL-AG, LNC-blank, LNC-AG and PNC-AG showed no
signiﬁcant reduction in cell viability or any substantial cell necrosis
at the test concentrations. Overall, the results observed in MTT and
LDH assays were comparable and the nanocarriers were nontoxicG (), AL-AG (&), LNC-AG (&) and PNC-AG (!) at 4 C up to 14 days; b) Apigenin
Fig. 4. a) Size distribution proﬁles of CL-AG, AL-AG, LNC-AG and PNC-AG in FBS at 37 C and 75 rpm after 6 h. b) Diameter of CL-AG, AL-AG, LNC-AG and PNC-AG in FBS at 37 C
and 75 rpm up to 24 h.
Fig. 5. Complement consumption at 37 C by CL-AG (), AL-AG (&), LNC-AG (&) and
PNC-AG (!).
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ing NDDS conc. are shown in Table 3).
4. Discussion
The aim of the present study was to develop injectable dosage
forms of AG, to allow their use for in vivo studies. AG showed many
promising pharmacological activities, but its in vivo use is
restricted due to very low aqueous solubility. As a result, very
slow dissolution would occur after oral administration, which is
the rate limiting step causing slow absorption and low bioavail-
ability (Zhang et al., 2013). In fact, a study on pharmacokinetics and
metabolism of AG reported that the drug reached the systemic
circulation 24 h after oral administration (Gradolatto et al., 2005).
Parenteral administration of AG solution formulations can
overcome the problem of bioavailability, but face challenges of
short plasma half-life (90–105 min) (Wan et al., 2007; Zhang et al.,
2013) and nonspeciﬁc high tissue distribution (Wan et al., 2007).
Moreover, rapid crystallization may occur when these formula-
tions are injected into blood which reduces its availability at
Fig. 6. Cytotoxicity of AG, CL-AG, CL-blank, AL-AG, AL-blank, LNC-AG, LNC-blank, PNC-AG and PNC-blank on EAhy926 cells. The cells were treated for 24 h. At the end of the
incubation period, cell viability was determined by the MTS reduction assay and cell necrosis was quantiﬁed by LDH assay, as described in Section 2.11. (Oneway ANOVA with
Dunnett’s post-test. p < 0.1 is denoted by (*), p < 0.01 by (**) and p < 0.001 by (***)).
Table 3
AG concentrations and corresponding NDDS concentrations.
AG conc. (mM) Corresponding NDDS concentration (mg/ml)
CL-AG AL-AG LNC-AG PNC-AG
40.0 683 1678 1744 756
10.0 171 420 436 189
2.5 43 105 109 47
0.6 10 25 26 11
764 R. Karim et al. / International Journal of Pharmaceutics 532 (2017) 757–768diseased tissue (Engelmann et al., 2002). In fact, Engelmann et al.
observed enlarged abdominal lymph nodes in mice caused by AG
deposition after treatment with such formulation of the drug
(Engelmann et al., 2002). Hence, it is necessary to develop suitable
drug carrier systems for AG with sufﬁcient stability during storage
and in serum. Therefore, three types of NDDSs of AG were
developed in this study i.e. liposomes, LNC and PNC; and were
evaluated as potential injectable formulations of AG. For PNC
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block-copolymer was used for the ﬁrst time. The amphiphilic
surface active properties of the polymer can aid to improve
nanocarrier stability which has been already described in the
literature (Lopalco et al., 2015). The use of polyphosphate backbone
instead of commonly utilized polylactide or polyglycolide chains is
more biocompatible as the degradation products of polyphos-
phates do not create extreme acidic environment (Yilmaz and
Jerome, 2016). The presence of tocopherol on the polyphosphate
chain helps to improve entrapment of hydrophobic drugs like AG
(Tripodo et al., 2015). Additionally, it may improve the stability of
AG by acting as an antioxidant and protecting its phenol groups
from oxidation.
Three key physicochemical properties of the nanocarriers
inﬂuence their in vivo behavior: particle size, surface charge and
surface coating (Straubinger et al., 1993). These properties must be
optimized in order to achieve favorable drug delivery. Particle size
is an important parameter which has profound impact on the
uptake of NDDSs by MPS. The rate of MPS uptake increases as size
of NDDSs increases (Senior et al., 1985). Size of the CL-AG, AL-AG
and PNC-AG were comparable, but the LNC-AG had smaller
diameter. Compared to AL-AG, the lipid bilayer of CL-AG had an
additional dimethylaminoethane-carbamoyl (DC-) chain on cho-
lesterol molecules which imparted a signiﬁcant positive surface
charge (as ionically bonded chloride ion dissociates from the
hydrochloride salt of tertiary amine group of the DC- chain in
aqueous environment) without affecting vesicle size. Although
most components of the nanocapsule structures of the LNC-AG and
PNC-AG were similar, the ratio of the excipients and manufacturing
techniques were different, resulting in nanocapsules with dissimi-
lar sizes. However, the major factor governing the higher size of the
PNC-AG is possibly its higher weight fraction of core-oil (69%)
compared to LNC-AG (50%), which is in accordance with previous
reports (Heurtault et al., 2003; Lertsutthiwong et al., 2008).
Though, size of all the NDDSs were within acceptable limits and
comparable with previously studied systemically administered
nanocarriers (Fu et al., 2009; Laine et al., 2014; Lim et al., 2015;
Mosqueira et al., 2001).
The surface charge of nanocarriers is another critical parameter
that is important from two perspectives- storage stability and in
vivo distribution. Charged NDDSs are less prone to particle
aggregation and more stable as dispersions, compared to neutral
nanocolloids. Moreover, their cellular-interaction capacity and
possibility of intracellular drug delivery are generally higher,
compared to neutral NDDSs. Macrophage engulfment of charged
nanocarriers increases as intensity of surface charge ampliﬁes,
whereas non-phagocytic cellular uptake increases the charge
moves towards comparatively more positive value (He et al., 2010).
The surface charges of the AG-loaded NDDSs can be ordered as
follows- CL-AG > PNC-AG > LNC-AG  AL-AG, where zeta potential
of only CL-AG was positive.
The presence of additional DC- chain on the cholesterol of the
lipid bilayer of CL-AG not only altered the zeta potential, but
improved the EE by 2 folds, compared to AL-AG. This is possibly due
to charged interaction between AG and the DC- chain. AG is a
weakly acidic molecule having two pKa values (6.6 and 9.3) (Favaro
et al., 2007), and therefore will be partially deprotonated at the pH
of the buffer (7.4) with an equilibrium between mono-anionic and
neutral species (Papay et al., 2016; Tungjai et al., 2008). Therefore,
the neutral species can be entrapped in the lipid bilayer and the
mono-anionic species can interact with the positively charged DC-
chain on the CL-AG surfaces, resulting signiﬁcantly improved drug
entrapment. Yuan et al. observed similar electrostatic and/or
hydrogen bond formation among AG and positively charged
human serum albumin (Yuan et al., 2007). Additionally, Papay et al.
reported probable electrostatic repulsion among AG andsulfobutylether-b-cyclodextrin, due to presence of negatively
charged sulfo group in the cyclodextrin which weakened their
complexation as pH was increased (Papay et al., 2016). Moreover,
the ionized DC- chain is present both at the inner and outer
surfaces of the lipid bilayer facing towards the aqueous core and
the surrounding aqueous environment respectively. As AG was
added during the formation of dry lipid ﬁlm, we hypothesize that
AG might be electrostatically attached with both inner and outer
surfaces during formation of the liposome. The phenomenon is
more evident from the drug release characteristics and storage
stability (chemical) of CL-AG which is explained in the respective
parts of the discussion. The nanocapsules had high EE which can be
possibly attributed to the presence of an oily core.
Drug loading capacity of the CL-AG was 2.5 folds higher
compared to AL-AG, due to the presence of the additional
positively charged DC- chain. Similarly, drug loading capacity of
PNC-AG was 2.3 folds more compared to LNC-AG, possibly due to
presence of higher% of core oil in its formulation (Lertsutthiwong
et al., 2008).
A major parameter evaluated in this study was the drug release
characteristics of the different NDDSs, to determine their
feasibility as extended release carriers of AG. In previous experi-
ments, plasma concentration of AG was high after intravenous
administration, but it rapidly fell with a half-life around 1.75 h
(Wan et al., 2007), which can be due to either crystallization of
apigenin in physiological pH (Engelmann et al., 2002), or formation
of its metabolites (Gradolatto et al., 2004). To prolong the
pharmacological activity, dosage forms having prolonged plasma
circulation time and extended release proﬁle can be beneﬁcial.
Drug release at 37 C in HEPES buffer (pH 7.4, 285–295 mOsm/kg)
from the liposomes was more rapid compared to the nanocapsules,
which can be attributed to the different composition and
morphology of the two types of nanocarriers. The nanocapsules
have an oily core surrounded by hydrophobic and amphiphilic
polymers. Therefore, majority of hydrophobic drugs like AG will be
encapsulated in the core of such nanocarriers. However, liposomes
entrap majority of AG within their lipid bilayer and thus released
the drug more easily compared to nanocapsules. The release rate
from CL-AG was comparatively slower than AL-AG, which can be
attributed to two possible reasons. Firstly, the possible electro-
static attraction of AG with the positively charged DC- chain can
hinder the movement of the drug from the lipid bilayer. Secondly,
the likelihood of presence of a portion of the entrapped AG at the
inner surface of the lipid bilayer of CL-AG (as some DC- chains will
be present at that surface) which provides more obstacles in the
movement pathway of the drug. However, the nanocapsules i.e.
LNC-AG and PNC-AG showed much sustained release character-
istics than the liposomes. The release rate of the nanocapsules was
comparable up to 24 h, but the PNC-AG showed slightly faster
release rate afterwards, compared to LNC-AG. The higher% of
excipients present on the LNC-AG shell (50% compared to 30% for
PNC-AG) may have produced a thicker wall which contributed to
the slower release rates at the later stages of the experiment
(Watnasirichaikul et al., 2002).
No drug leakage was observed from any of the NDDSs during
the storage stability study (14 days at 4 C) showing the robustness
of the nanocarriers. Sizes of all the nanocarriers were also stable
under the same conditions, and all of them remained mono-
dispersed, demonstrating physical stability of the NDDSs. Howev-
er, the AG concentration gradually decreased to 90% after 14 days at
4 C in case of CL-AGs. Based on the difference in the formulation,
EE and drug loading capacity of the liposomes, a large portion of
the entrapped AG may be present at the surfaces of the CL-AG
which puts the drug in contact of the aqueous environment during
storage. This may lead to chemical modiﬁcation or degradation, as
pure apigenin is known to be an unstable molecule (Patel et al.,
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2006). Further study would be necessary to conﬁrm the mecha-
nism of the possible apigenin degradation. However, AG concen-
tration did not alter throughout the experiment period for AL-AG,
LNC-AG and PNC-AG. Therefore, these NDDSs can be used to
improve aqueous solubility and stability of AG. None of the NDDSs
showed any drug leakage at 4 C up to 14 days.
The behavior of nanocarriers at the “bio-nano interface” must
be evaluated to predict their in vivo fate (Nel et al., 2009; Palchetti
et al., 2016). Formation of protein corona around nanocarriers is
dependent on their composition, diameter, shape and surface
properties along with several experimental parameters, e.g protein
concentration, temperature, incubation time and incubation
condition (static vs dynamic) etc. (Caracciolo, 2015; Palchetti
et al., 2016). From relatively small to huge amounts of proteins may
get adsorbed on the nanovector surface, and if plasma opsonins are
adsorbed, the NDDSs will be removed from the systemic
circulation by the MPS (Palchetti et al., 2016). Additionally, NDDSs
can be destabilized or form aggregates in presence of serum
proteins which will alter their in vivo fate. After injection into
systemic circulation, NDDSs will be dispersed, diluted and
surrounded by high amounts of proteins very quickly. Therefore,
it is necessary to keep nanocarrier concentration as low as possible,
compared to serum proteins, while evaluating their stability in
serum. The total concentration of serum proteins (average
concentration calculated based on manufacture speciﬁcations)
was 188 folds higher than concentration of the CL-AG, AL-AG and
PNC-AG, and 75 folds higher than the LNC-AG, in the nanocarrier-
FBS mixtures used in this study. None of the NDDSs showed any
signs of particle aggregation or protein corona formation up to 6 h,
which indicates that the PEG chains on their surface were adequate
to efﬁciently repel the serum proteins. Although some peaks of
larger aggregates were observed in DLS after 24 h in case of CL-AG,
AL-AG and LNC-AG, it is not conclusive that they adsorbed proteins
on their surface as the control FBS also showed peaks around 200–
500 nm at this time point. The nanocarriers may gradually lose
their ability to repel proteins due to desorption of PEG chains from
their surface, which occurs in a time-dependent way (Nag and
Awasthi, 2013; Nag et al., 2013). Conversely, the larger peaks on the
NDDS-FBS mixture also may appear due to the aggregated particles
from FBS, which overlapped the peaks of the nanocarriers and
shifted the peaks toward a higher value. The PNC-AG did not show
any signs of particle aggregation or protein adsorption up to 24 h,
but its peak shifted slightly towards smaller diameter (approxi-
mately 35 nm). As the PNC-AG was prepared using nanoprecipi-
tation technique, tiny aqueous cavities may get entrapped within
its oily core (Rabanel et al., 2014). Water from NDDS core may not
escape to the exterior during storage as the particle core and shell
membrane are less ﬂuid at colder storage temperature (therefore
no change in particle size is observed during storage), but can
gradually come out when the NDDS is at physiological temperature
in presence of serum due to altered osmotic pressure (Wolfram
et al., 2014). Finally, the experiment showed that all of the
developed NDDSs (CL-AG, AL-AG, LNC-AG and PNC-AG) were
stable after large dilution in serum and did not form signiﬁcant
aggregates or protein corona for extended period which demon-
strates their prolonged stability in serum.
Additionally, complement consumption of the NDDSs in human
serum was evaluated by CH50 assay, as high consumption can lead
to a rapid activation of the complement system and can be
followed by clearance from bloodstream. The CH50 assay is an
efﬁcient technique for measuring the activation of the total
complement system. It correlates well with other complement
activation evaluation methods i.e. crossed immunoelectrophoresis
and enzyme-linked immunosorbent assay, and represents also a
good preliminary experiment to predict the stealth properties ofnanocarriers intended for systemic administration (Meerasa et al.,
2011). However, previous studies reporting complement con-
sumption of nanocarriers (Cajot et al., 2011; Vonarbourg et al.,
2006) plotted percentage of CH50 unit consumption against
theoretical surface area of the particles which was calculated using
an arbitrary density value. In contrast, NTA was used in this study
to determine the number of nanocarriers per mL of NHS. Surface
area was calculated using this number and the mean diameter of
the NDDS. The previous method of theoretical surface area
calculation produced values much higher (1474–1616 cm2/mL of
NHS for the NDDS samples in this study) than the actual surface
area obtained by NTA. Therefore, careful consideration is necessary
when comparing the results with previous reports. The lowest
CH50 unit consumption was observed for LNC-AG, which is in
agreement with the results described by Vonarbourg et al. and can
be possibly attributed to its smaller size (Vonarbourg et al., 2006)
and higher percentage of PEG in its composition (due to presence
of Kolliphor1 HS15 and DSPE-mPEG2000) (Jeon et al., 1991)
compared to the other NDDSs. Although, mean diameter of CL-
AG, AL-AG and PNC-AG were similar, their CH50 unit consumption
was different. Complement consumption of CL-AG was compara-
ble with AL-AG up to 600 cm2/mL of NHS, but augmented
comparatively faster then, possibly due to its positive surface-
charge (Capriotti et al., 2012). Complement activation of PNC-AG
was higher at surface area <600 cm2 compared to other three
NDDSs, but reached only 23.7% at 832 cm2/mL of NHS. The
difference can be due to several factors i.e. composition, PEG chain
conformation, PEG density or presence of surfactant coating (PS80)
(Gao and He, 2014). Further study would be necessary to validate
the precise reason. Overall, the NDDSs did not show any strong
complement consumption and should not be rapidly removed
from systemic circulation by MPS.
Toxicity of the NDDSs on a human endothelial cell line
(EAhy926) was evaluated to assess their injectability. The
commonly used cytotoxic assays works by different mechanisms
and their sensitivity can be dissimilar with alteration of cell lines
(Fotakis and Timbrell, 2006; Lappalainen et al., 1994; Lobner,
2000). Moreover, presence of nanoparticles (Holder et al., 2012;
Kroll et al., 2009) or the drug molecule (Wang et al., 2010) may
interfere with the assay procedures and provide misleading
results. Therefore, two common cytotoxicity assays i.e. MTS and
LDH assays were used for evaluation and comparison of the
possible toxic effects of the NDDSs on the endothelial cells. The two
methods for cytotoxicity assessment provided similar results.
Among the NDDSs, only CL-AG showed signiﬁcant toxicity in a dose
dependent manner in both assays at concentrations above 171 mg/
mL. This is probably due to the presence of the tertiary nitrogen
group containing cationic cholesterol derivative (DC-Chol) in CL-
AG, which can act as protein kinase C inhibitor and result toxicity
(Lv et al., 2006). In comparison, the AL-AG, LNC-AG and PNC-AG
were nontoxic at their maximum test concentrations (420, 436 and
189 mg/mL respectively). Overall, the NDDSs were nontoxic up to
high concentrations and can be considered suitable as injectable
AG-loaded nanovectors.
5. Conclusion
In this study, novel AG-loaded NDDSs, i.e. liposomes, LNC and
PNC were developed as potential injectable dosage forms of AG.
The nanovectors were characterized by their size, surface charge,
EE, mass yield and drug loading capacity. Moreover, drug release
property, drug leakage possibility and stability during storage were
evaluated. Furthermore, stability of the NDDSs in serum at
physiological temperature and cytotoxicity on a human macro-
vascular endothelial cell line was evaluated. The size of all the
NDDSs was within the acceptable limit for injectable nanocarriers.
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negatively charged (AL-AG, LNC-AG and PNC-AG) which hinder
particle aggregation and provided stability during storage.
Presence of DC-Chol showed signiﬁcant increase in AG entrapment
at physiological pH, and application of such cationic lipids to
improve AG encapsulation can be utilized in future NDDS
development of the drug. Although, toxicity due to cationic lipids
and chemical stability of the drug have to be carefully considered.
Presence of oily core in the NDDSs was beneﬁcial for AG
encapsulation, and the LNC-AG and PNC-AG showed high EE.
Moreover, this is the ﬁrst study reporting the suitability and use of
the tocopherol grafted PEG-b-polyphosphate amphiphilic block-
copolymer PEG120-b-(PBP-co-Ptoco)9 for stable nanocapsule prep-
aration.
Finally, all the nanovectors were stable in FBS for extended
periods, showed weak complement system activation and were
non-toxic to human macrovascular endothelial cells up to high
concentrations, and therefore were suitable as injectable nano-
carriers of AG. Due to less pronounced burst effect and extended
release characteristics, the nanocapsule formulations i.e. LNC-AG
and PNC-AG could be favorable approach for achieving prolonged
pharmacological activity or tumor-targeted delivery of AG using
injectable NDDS.
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